VVD-133214

DRUG2 trials

Sponsors

Vividion Therapeutics, Inc.

Conditions

Advanced Solid TumorsColorectal AdenocarcinomaColorectal Cancer

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

RecruitingNCT06004245

Vividion Therapeutics, Inc.Advanced Solid Tumors, Colorectal Cancer

Start: 2024-01-25End: 2027-05-31Target: 280Updated: 2026-09-18

Phase 2

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

RecruitingNCT07811193

Vividion Therapeutics, Inc.Colorectal Adenocarcinoma

Start: 2026-09-11End: 2030-12-31Target: 140Updated: 2026-09-16

Related Papers

Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors

Cancer Research2025-04-254 citations